Loading...

Onxeo

ENXTPA:ONXEO
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ONXEO
ENXTPA
€45M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
ONXEO Share Price and Events
7 Day Returns
0.6%
ENXTPA:ONXEO
1.5%
FR Biotechs
1.9%
FR Market
1 Year Returns
-36.1%
ENXTPA:ONXEO
-33.5%
FR Biotechs
-2.3%
FR Market
ONXEO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Onxeo (ONXEO) 0.6% -0.5% -9.6% -36.1% -73.7% -89.6%
FR Biotechs 1.5% -2.5% 2.9% -33.5% -50.4% -32.4%
FR Market 1.9% -2.3% 5.9% -2.3% 30.8% 29.8%
1 Year Return vs Industry and Market
  • ONXEO underperformed the Biotechs industry which returned -33.5% over the past year.
  • ONXEO underperformed the Market in France which returned -2.3% over the past year.
Price Volatility
ONXEO
Industry
5yr Volatility vs Market
Related Companies

ONXEO Value

 Is Onxeo undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Onxeo. This is due to cash flow or dividend data being unavailable. The share price is €0.83.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Onxeo's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Onxeo's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:ONXEO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.18
ENXTPA:ONXEO Share Price ** ENXTPA (2019-05-17) in EUR €0.83
France Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 18.19x
France Market PE Ratio Median Figure of 418 Publicly-Listed Companies 17.81x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Onxeo.

ENXTPA:ONXEO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ONXEO Share Price ÷ EPS (both in EUR)

= 0.83 ÷ -0.18

-4.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Onxeo is loss making, we can't compare its value to the FR Biotechs industry average.
  • Onxeo is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Onxeo's expected growth come at a high price?
Raw Data
ENXTPA:ONXEO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
France Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 0.34x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Onxeo, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Onxeo's assets?
Raw Data
ENXTPA:ONXEO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.85
ENXTPA:ONXEO Share Price * ENXTPA (2019-05-17) in EUR €0.83
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.33x
France Market PB Ratio Median Figure of 619 Publicly-Listed Companies 1.44x
ENXTPA:ONXEO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ONXEO Share Price ÷ Book Value per Share (both in EUR)

= 0.83 ÷ 0.85

0.97x

* Primary Listing of Onxeo.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Onxeo is good value based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess Onxeo's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Onxeo has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ONXEO Future Performance

 How is Onxeo expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Onxeo expected to grow at an attractive rate?
  • Unable to compare Onxeo's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Onxeo's earnings growth to the France market average as no estimate data is available.
  • Unable to compare Onxeo's revenue growth to the France market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTPA:ONXEO Future Growth Rates Data Sources
Data Point Source Value (per year)
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 32.7%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 39.4%
France Market Earnings Growth Rate Market Cap Weighted Average 13.2%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:ONXEO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:ONXEO Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 4 -12 1
ENXTPA:ONXEO Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 6 -11 -9
2018-09-30 7 -17 -33
2018-06-30 8 -22 -56
2018-03-31 9 -25 -58
2017-12-31 10 -28 -59
2017-09-30 8 -23 -41
2017-06-30 6 -19 -23
2017-03-31 5 -18 -23
2016-12-31 4 -18 -23
2016-09-30 4 -20 -21
2016-06-30 4 -23 -19
2016-03-31 4 -23 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Onxeo is high growth as no earnings estimate data is available.
  • Unable to determine if Onxeo is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:ONXEO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Onxeo Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ONXEO Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 -0.23 -0.23 -0.23 1.00
ENXTPA:ONXEO Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.18
2018-09-30 -0.63
2018-06-30 -1.11
2018-03-31 -1.14
2017-12-31 -1.17
2017-09-30 -0.80
2017-06-30 -0.45
2017-03-31 -0.46
2016-12-31 -0.48
2016-09-30 -0.48
2016-06-30 -0.47
2016-03-31 -0.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Onxeo will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Onxeo's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Onxeo has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ONXEO Past Performance

  How has Onxeo performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Onxeo's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Onxeo does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Onxeo's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Onxeo's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Onxeo's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Onxeo Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ONXEO Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6.13 -9.40 14.17
2018-09-30 7.18 -32.84 16.73
2018-06-30 8.24 -56.28 19.29
2018-03-31 8.87 -57.68 22.53
2017-12-31 9.51 -59.07 25.77
2017-09-30 7.71 -41.07 25.67
2017-06-30 5.91 -23.07 25.56
2017-03-31 5.17 -22.87 24.84
2016-12-31 4.42 -22.67 24.11
2016-09-30 4.12 -20.98 23.52
2016-06-30 3.83 -19.29 22.92
2016-03-31 3.65 -19.35 23.00
2015-12-31 3.48 -19.41 23.08
2015-09-30 13.22 -12.75 23.56
2015-06-30 22.96 -6.09 24.05
2015-03-31 22.52 -6.90 22.36
2014-12-31 22.08 -7.70 20.68
2014-09-30 11.68 -14.24 18.64
2014-06-30 1.27 -20.79 16.60
2014-03-31 1.37 -18.06 16.32
2013-12-31 1.47 -15.32 16.03
2013-09-30 2.75 -13.26 15.04
2013-06-30 4.03 -11.20 14.02
2013-03-31 4.03 -11.37 13.39
2012-12-31 4.03 -11.55 12.76
2012-09-30 3.46 -12.63 13.45
2012-06-30 2.89 -13.71 14.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Onxeo has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Onxeo has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Onxeo improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Onxeo's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Onxeo has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ONXEO Health

 How is Onxeo's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Onxeo's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Onxeo is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Onxeo's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Onxeo's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Onxeo Company Filings, last reported 4 months ago.

ENXTPA:ONXEO Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 45.40 7.04 11.25
2018-09-30 45.40 7.04 11.25
2018-06-30 42.25 0.10 11.01
2018-03-31 42.25 0.10 11.01
2017-12-31 49.87 0.13 14.28
2017-09-30 49.87 0.13 14.28
2017-06-30 96.81 0.16 27.65
2017-03-31 96.81 0.16 27.65
2016-12-31 94.09 0.11 29.24
2016-09-30 94.09 0.11 29.24
2016-06-30 94.21 0.07 19.60
2016-03-31 94.21 0.07 19.60
2015-12-31 102.80 0.07 33.79
2015-09-30 102.80 0.07 33.79
2015-06-30 110.69 1.78 42.92
2015-03-31 110.69 1.78 42.92
2014-12-31 121.97 1.63 57.23
2014-09-30 121.97 1.63 57.23
2014-06-30 78.45 0.11 19.07
2014-03-31 78.45 0.11 19.07
2013-12-31 7.89 0.09 11.33
2013-09-30 7.44 0.09 11.33
2013-06-30 6.54 0.11 11.92
2013-03-31 6.54 0.11 11.92
2012-12-31 11.74 0.06 14.50
2012-09-30 11.74 0.06 14.50
2012-06-30 15.17 2.31 20.39
  • Onxeo's level of debt (15.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.1% vs 15.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Onxeo has less than a year of cash runway based on current free cash flow.
  • Onxeo has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.3% each year.
X
Financial health checks
We assess Onxeo's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Onxeo has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ONXEO Dividends

 What is Onxeo's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Onxeo dividends. Estimated to be 0% next year.
If you bought €2,000 of Onxeo shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Onxeo's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Onxeo's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:ONXEO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
France Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 1%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:ONXEO Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Onxeo has not reported any payouts.
  • Unable to verify if Onxeo's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Onxeo's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Onxeo has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Onxeo's dividends in 3 years as they are not expected to pay a notable one for France.
X
Income/ dividend checks
We assess Onxeo's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Onxeo afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Onxeo has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ONXEO Management

 What is the CEO of Onxeo's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Judith Greciet
COMPENSATION €646,861
AGE 50
TENURE AS CEO 7.9 years
CEO Bio

Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operations and R&D at Onxeo SA since March 1, 2011. Ms. Greciet served as Deputy Chief Operating Officer of BioAlliance Pharma since March 2011. Ms. Greciet has an exemplary career in the pharmaceutical industry and international groups. Ms. Greciet joined Eisai France in June 2007 after successful achievements at Wyeth Pharmaceuticals France (today Pfizer), LFB Group (Laboratoire Francais du fractionnement et des Biotechnologies, a French bio-pharmaceutical company), Zeneca and Pharmacia, where she held increasing operational and strategic positions involving a managerial scope. She particularly focused on optimizing links with all health actors (researchers, academic practitioners, medical doctors, patient associations, health authorities.). She exercised her talents in the oncology and immunology areas with innovative products such as Enbrel (in rheumatology). She has served successively as Head of the Oncology Department and of the Hospital Department where she was notably in charge of hospital antibiotherapy projects. She has been a Director of Onxeo SA since June 29, 2011. She holds a Doctorate of Pharmacy in addition to being a graduate of 3(rd) cycle management and pharmaceutical marketing.

CEO Compensation
  • Judith's compensation has increased whilst company is loss making.
  • Judith's remuneration is higher than average for companies of similar size in France.
Management Team Tenure

Average tenure and age of the Onxeo management team in years:

3.7
Average Tenure
50
Average Age
  • The tenure for the Onxeo management team is about average.
Management Team

Judith Greciet

TITLE
CEO & Director
COMPENSATION
€647K
AGE
50
TENURE
7.9 yrs

Nicolas Fellmann

TITLE
CFO & Administrative and Finance Director
AGE
50
TENURE
12.5 yrs

Françoise Bono

TITLE
Chief Scientific Officer
TENURE
2.2 yrs

Audrey Legentil-Dumery

TITLE
Director of Human Resources
TENURE
4.3 yrs

Michel Forest

TITLE
Chief Pharmacist & Quality Assurance Director

Philippe Maitre

TITLE
Chief of US Operations & Executive VP
AGE
61
TENURE
3.2 yrs

Olivier de Beaumont

TITLE
Chief Medical Officer
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Onxeo board of directors in years:

3.2
Average Tenure
59
Average Age
  • The tenure for the Onxeo board of directors is about average.
Board of Directors

Joe Zakrzewski

TITLE
Chairman
COMPENSATION
€74K
AGE
56
TENURE
3.3 yrs

Judith Greciet

TITLE
CEO & Director
COMPENSATION
€647K
AGE
50
TENURE
7.9 yrs

Thomas Hofstaetter

TITLE
Independent Director
COMPENSATION
€26K
AGE
70
TENURE
7 yrs

Danièle Guyot-Caparros

TITLE
Senior Independent Director
COMPENSATION
€24K
AGE
60
TENURE
3.3 yrs

Tomas Lindahl

TITLE
Chairman of Scientific Advisory Board
TENURE
1.5 yrs

Nicolas Trebouta

TITLE
Representative Director
AGE
55
TENURE
7.9 yrs

Jean-Pierre Kinet

TITLE
Independent Director
COMPENSATION
€19K
AGE
65
TENURE
3.1 yrs

Jean-Pierre Bizzari

TITLE
Independent Director
COMPENSATION
€21K
AGE
64
TENURE
3.1 yrs

Christine Garnier

TITLE
Independent Director
COMPENSATION
€17K
AGE
57
TENURE
2.1 yrs

Elvira Urgoiti

TITLE
Independent Director
COMPENSATION
€18K
AGE
59
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Onxeo's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Onxeo has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ONXEO News

Simply Wall St News

Does Onxeo SA (EPA:ONXEO) Have A Volatile Share Price?

If you're interested in Onxeo SA (EPA:ONXEO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

If You Had Bought Onxeo (EPA:ONXEO) Stock Five Years Ago, You'd Be Sitting On A 89% Loss, Today

For example, we sympathize with anyone who was caught holding Onxeo SA (EPA:ONXEO) during the five years that saw its share price drop a whopping 89%. … Onxeo isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last five years Onxeo saw its revenue shrink by 6.5% per year.

Simply Wall St -

Does Onxeo SA's (EPA:ONXEO) CEO Salary Compare Well With Others?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Judith Greciet's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below €176m

Simply Wall St -

Does Onxeo SA (EPA:ONXEO) Have A High Beta?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Here's What We Think About Onxeo SA's (EPA:ONXEO) CEO Pay

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Judith Greciet's Compensation Compare With Similar Sized Companies. … According to our data, Onxeo SA has a market capitalization of €46m, and pays its CEO total annual compensation worth €647k.

Simply Wall St -

Analysts Expect Breakeven For Onxeo SA (EPA:ONXEO)

Onxeo SA's (EPA:ONXEO):. … Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. … Many investors are wondering the rate at which ONXEO will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Why I Sold Onxeo SA (EPA:ONXEO)

ONXEO has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like ONXEO as a business is its low level of fixed assets on its balance sheet (0.48% of total assets). … ONXEO has virtually no fixed assets, which minimizes its downside risk.

Simply Wall St -

ONXEO Company Info

Description

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in clinical development stage for the treatment of metastatic melanoma; and Validive, which completed Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; and a license agreement with Monopar Therapeutics Inc. to develop Validive. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France.

Details
Name: Onxeo SA
ONXEO
Exchange: ENXTPA
Founded: 1997
€45,405,393
54,705,293
Website: http://www.onxeo.com
Address: Onxeo SA
49, boulevard du Général Martial Valin,
Paris,
Ile-de-France, 75015,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ONXEO Ordinary Shares Euronext Paris FR EUR 08. Dec 2005
OTCPK OXNX.F Ordinary Shares Pink Sheets LLC US USD 08. Dec 2005
DB C4X Ordinary Shares Deutsche Boerse AG DE EUR 08. Dec 2005
LSE 0NWK Ordinary Shares London Stock Exchange GB EUR 08. Dec 2005
CPSE ONXEO Ordinary Shares OMX Nordic Exchange Copenhagen DK DKK 08. Dec 2005
BATS-CHIXE ONXEOP Ordinary Shares BATS 'Chi-X Europe' GB EUR 08. Dec 2005
Number of employees
Current staff
Staff numbers
30
Onxeo employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 20:35
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/03/12
Last earnings filing: 2019/04/09
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.